Stromedix, Inc.

Biogen recently has been working to diversify its portfolio and reduce the risk level in its research and development pipeline, but BG00011 for idiopathic pulmonary fibrosis (IPF) will no longer cont

Arrakis Therapeutics Inc. is in the middle of a big pivot from building its platform for the discovery of small molecules that target RNA to generating a pipeline of drug candidates – and now it has

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bio

Michael Gilman didn't have much time to enjoy "retirement" after Bristol-Myers Squibb Co. acquired his last company Padlock Therapeutics Inc. for up to $600m. Within months he was immersed in